Therapy News and Research

RSS

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of patients with refractory advanced colorectal cancer.

9 Apr 2010

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Cell Therapeutics, Inc. today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Pixuvri™ (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL").

9 Apr 2010

Miami Medicare case spotlights federal probes into HIV therapy fraud

A new Miami Medicare fraud case spotlights federal investigations of massive scams using HIV therapies.

9 Apr 2010

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Biopartners GmbH has announced that it has received EU marketing authorization from the European Commission for Ribavirin Biopartners 200mg film-coated tablets. The product is intended for the treatment of chronic hepatitis C infection as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b.

9 Apr 2010

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

9 Apr 2010

ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer

ZIOPHARM Oncology, Inc., announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer.

9 Apr 2010

Dealing with emotional impacts of bullying before it's too late

The California Association of Marriage and Family Therapists (CAMFT) encourages parents to talk with teens about bullying before it's too late. A conversation can be an important first step in identifying a bullying problem and stopping the abuse before it goes too far.

8 Apr 2010

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Oncolytics Biotech Inc. announced today that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin Harrington of the Institute of Cancer Research, London, UK, was published in the online version of the Journal of Clinical Investigation on April 1, 2010.

8 Apr 2010

No risk of adverse interaction between PPIs and clopidogrel

New research by the University of East Anglia (UEA) shows no risk in combining two commonly-prescribed treatments for patients at risk of heart attacks and strokes.

8 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

LSDF announces $15M in program grant to enhance diagnosis and treatment of cancer

The Life Sciences Discovery Fund today announced nearly $15 million in program grant awards to support collaborative research initiatives spearheaded by three Washington state life sciences organizations.

8 Apr 2010

UNC Charlotte researcher improves lives of families and children affected by birth defects

Birth defects remain a leading cause of death in the first year of life. According to the March of Dimes, every 3 to 4 minutes a baby is born with a birth defect in the United States. About 1 in every 33 infants is affected by birth defects.

8 Apr 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is expressed on malignant Hodgkin lymphoma cells.

8 Apr 2010

Martina undergoing therapy for breast cancer, urges women to be more vigilant

The tennis legend Martina Navratilova has revealed on Wednesday that she is undergoing therapy for breast cancer. She has always been revered for her health and performance. Just a month short of her 50th birthday, Navratilova won her last grand slam title, the mixed doubles at the 2006 US Open, and in retirement she wrote a 'how-to' book about good living. She was a winner of a record nine Wimbledon singles titles, 59 grand slam titles, including 18 singles trophies and arguably the greatest female athlete of all time.

8 Apr 2010

Clinical testing service for safer dosing of warfarin

Machaon Diagnostics, California's only independent laboratory for testing bleeding and clotting disorders has launched a clinical testing service for patients that have been prescribed warfarin. Warfarin, also known as Coumadin, Jantoven or warfarin sodium, is a potent 'blood thinner' or anticoagulant.

8 Apr 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick - pointing to a greater need for awareness and education around the condition and its treatment.

From Baxter International Inc. 8 Apr 2010

First proton therapy center for New Jersey

Cancer survivors joined representatives from ProCure Treatment Centers, Inc., Princeton Radiation Oncology, and CentraState Healthcare System to break ground on the ProCure Proton Therapy Center in Somerset - the first proton therapy center to be built in the state, located 40 miles from downtown Manhattan.

8 Apr 2010

Complex back surgeries skyrocket, raising concerns about cost, complications

NPR: "Too many complex back surgeries are being done and people are suffering as a result, according to a study in the current issue of the Journal of the American Medical Association. The general tendency noted in the study — that many patients and doctors think more medical care is always better — has implications for the new health overhaul law.

8 Apr 2010

Researchers find new genomic approach to identify smokers at risk of lung cancer

Researchers from Boston University School of Medicine in collaboration with investigators at the University of Utah, have discovered a new approach for identifying smokers at the highest risk for developing lung cancer. The findings, which appear in the April 7th issue of Science Translational Medicine, will allow the researchers to use a genomic approach to prevent lung cancer in these individuals and to personalize cancer chemoprophylaxis and therapy.

8 Apr 2010

Therapy News and Research

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Miami Medicare case spotlights federal probes into HIV therapy fraud

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Æterna Zentaris commences perifosine Phase 3 registration trial

ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer

Dealing with emotional impacts of bullying before it's too late

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

No risk of adverse interaction between PPIs and clopidogrel

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

LSDF announces $15M in program grant to enhance diagnosis and treatment of cancer

UNC Charlotte researcher improves lives of families and children affected by birth defects

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Martina undergoing therapy for breast cancer, urges women to be more vigilant

Clinical testing service for safer dosing of warfarin

Parents lack understanding of causes, signs and symptoms of dehydration in children

First proton therapy center for New Jersey

Complex back surgeries skyrocket, raising concerns about cost, complications

Researchers find new genomic approach to identify smokers at risk of lung cancer

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News